Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Propofol hemisuccinate - Epalex

Next Previous
Drug Profile

Propofol hemisuccinate - Epalex

Alternative Names: EP-102 - Epalex-; EP-103 - Epalex

Latest Information Update: 28 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Epalex
  • Class Antiepileptic drugs; General anaesthetics; Phenols; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Migraine
  • No development reported Epilepsy

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for preclinical development in Epilepsy in USA (Inhalation)
  • 30 May 2019 Investigation in Migraine in USA (PO) (Epalex pipeline, May 2019)
  • 29 May 2019 Preclinical trials in Epilepsy in USA (Inhalation) (Epalex pipeline, May 2019)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top